Illumina, Inc.

Analysis of ILMN Stock

Technical Perspective ILMN shows mixed signals, with recent weakness offset by solid intermediate-term gains. The 12% one-month decline appears to be a pullback after strong performance, potentially creating a buying opportunity as the stock moves from overbought to more neutral territory. However, its high beta of 1.4 indicates continued volatility, requiring investor tolerance for price swings.

Fundamental Assessment Fundamentally, ILMN demonstrates improving operational strength with sequential revenue growth and a significant expansion in net profit margin to 28.8%. The company maintains adequate liquidity with a current ratio above 2, though its extended cash conversion cycle suggests room for operational improvement. Return on equity of 12.3% reflects decent capital efficiency.

Valuation & Risk Considerations Valuation metrics present a compelling case with a forward P/E of 15.4 and exceptionally low PEG ratio of 0.13, indicating potential undervaluation relative to growth prospects. Primary risks include above-market volatility and sector-specific challenges in the genomics industry, though the absence of significant short interest suggests limited bearish sentiment.

Investment Recommendation ILMN presents a compelling opportunity for growth-oriented investors comfortable with moderate volatility. The combination of improved profitability, reasonable valuation metrics, and strong recovery potential from recent pullbacks supports a positive outlook. While operational efficiencies could be enhanced, the company's fundamental trajectory and attractive PEG ratio justify consideration for portfolio allocation. Note: This is not investment advice, for reference only.

RockFlow Model Forecast: Three Scenarios for 2026

Based on my analysis of ILMN, the 12-month outlook leans positive, driven by improving fundamentals and attractive valuation, though volatility remains a key factor.

The primary catalyst is the company's strengthened profitability, evidenced by sequential revenue growth and a significant net margin expansion to 28.8%. This operational improvement, combined with a compelling PEG ratio of 0.13, suggests strong potential for price appreciation if growth continues. The main risk is the stock's high volatility, indicated by its beta of 1.4, which makes it susceptible to broad market swings. While an explicit analyst target isn't provided, the combination of a reasonable forward P/E (15.4) and strong growth prospects suggests a target price range that could reasonably challenge the $150-$170 level over the next year, contingent on successful execution and stable market conditions.

Wall Street Consensus

Most Wall Street analysts are optimistic about Illumina, Inc.'s 12-month outlook, with consensus target around $134.46, indicating expected upside potential.

Overall, ILMN has investment potential but also faces challenges. Here are key factors to weigh before investing.

ILMN has delivered mixed performance with notable recent weakness but maintaining solid gains against the market over the intermediate term. The stock has demonstrated significant recovery from its 52-week lows while currently pulling back from recent highs following a substantial one-month decline. Volatility remains elevated as indicated by the stock's beta exceeding 1.4, reflecting higher sensitivity to market movements.

Recent performance shows concerning short-term momentum with a 12% decline over one month, though ILMN maintains a positive 6% return over three months that modestly outperforms the broader market by approximately 2.5%. This disparity suggests the stock experienced significant profit-taking recently after strong intermediate-term gains, potentially reflecting sector-specific headwinds or company-specific developments.

Currently trading approximately 15% below its 52-week high but still 92% above its 52-week low, ILMN sits in the upper-middle portion of its yearly range after the recent correction. The substantial recovery from lows coupled with the recent pullback suggests the stock may be transitioning from an overbought condition toward more neutral territory, though volatility remains elevated given its high beta characteristics.

Revenue & Profitability ILMN demonstrated sequential revenue growth from $1.08B in Q3 to $1.16B in Q4 2025, alongside a substantial improvement in net profit margin from 13.9% to 28.8%. The expansion in profitability was driven by steady gross margins near 67% and controlled operating expenses, enabling stronger bottom-line performance despite a flat interest expense environment.

Financial Health The company maintains a solid liquidity position with a current ratio of 2.08 and a cash ratio of 0.89, supported by ample cash per share of $10.67. However, ILMN operates with a moderate debt-to-equity ratio of 0.94 and a total debt-to-capitalization of 48%, while its cash flow-to-debt ratio of 0.13 indicates adequate but not strong debt coverage capacity.

Operational Efficiency ILMN's return on equity of 12.3% reflects respectable profitability on shareholder capital, though asset turnover remains low at 0.17 due to a high asset base. The extended cash conversion cycle of 143 days, driven by high days inventory outstanding (133 days), suggests room for improvement in working capital management and inventory efficiency.

Based on the available metrics, ILMN appears reasonably valued to slightly undervalued based on forward earnings expectations. The forward P/E of 15.4 is significantly lower than the TTM P/E of 22.9, suggesting strong projected earnings growth that justifies a lower multiple. Furthermore, the exceptionally low PEG ratio of 0.13, which is well below 1.0, strongly indicates the stock is undervalued when its earnings growth rate is factored in, despite the high EV/EBITDA ratio pointing to substantial current enterprise value relative to cash earnings.

A peer comparison is not feasible as industry average data is unavailable. Therefore, the assessment must rely solely on ILMN's standalone metrics. The low PEG ratio remains the most compelling signal, typically suggesting undervaluation relative to growth potential, but this conclusion would be strengthened by contextual industry benchmarks for the P/E and EV/EBITDA ratios.

Volatility Risk: ILMN's beta of 1.449 indicates the stock is approximately 45% more volatile than the broader market, presenting significant price fluctuation risk for investors. This elevated volatility is corroborated by a substantial one-year maximum drawdown of -25.66%, demonstrating a meaningful potential for capital depreciation during market downturns.

Other Risks: While the absence of significant short interest suggests a lack of pervasive negative sentiment from sophisticated investors, this does not eliminate other fundamental risks. The company remains exposed to sector-specific pressures, such as intense competition, regulatory changes affecting the genomics and life sciences tools industry, and potential disruptions to its research and development pipeline.